The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
=== Apodization in signal processing === The term apodization is used frequently in publications on Fourier-transform infrared (FTIR) signal processing. An example of apodization is the use of the Hann window in fast Fourier transform analyzers to smooth the discontinuities at the beginning and end of the sampled time record.
A high dosage of CPA given starting 7 days prior to initiation of GnRH agonist therapy was found to prevent the GnRH agonist-induced flare in testosterone levels. The combination of 100 mg/day CPA and 0.1 mg/day diethylstilbestrol given starting 4 weeks before GnRH-agonist introduction has also been found to prevent the GnRH agonist-induced testosterone flare. CPA should be given continuously for at least a week prior to GnRH agonist initiation for an optimal preventative effect on the GnRH agonist-induced testosterone flare.
While the Cro-Magnons are usually assumed to have generally practised sexual division of labour with men hunting and women gathering such as in the preponderance of recent hunter-gatherer societies, it is unclear to what extent this may be applied to Neanderthals. Both Neanderthal men and women have similar traumatic injury patterns, which might imply that both sexes were involved in hunting. Dental wearing patterns among Neanderthals, on the other hand, could indicate men and women typically carried different items with their mouths, though these may not have been related to subsistence tasks. The women at El Sidrón Cave, Spain, may have been eating more seeds and nuts than the men. The lack of distinctive task specialization in Neanderthals has usually been linked to their small population and group size, falling short of the demographic threshold where task specialization becomes feasible — which may also explain the comparative simplicity of Neanderthal material culture.
Ginkgo prefers full sun and grows best in environments that are well-watered and well-drained. The species shows a preference for disturbed sites; in the "semiwild" stands at Tianmu Mountains, many specimens are found along stream banks, rocky slopes, and cliff edges. Accordingly, ginkgo retains a prodigious capacity for vegetative growth. It is capable of sprouting from embedded buds near the base of the trunk (lignotubers, or basal chichi) in response to disturbances, such as soil erosion. Old specimens are also capable of producing aerial roots on the undersides of large branches in response to disturbances such as crown damage; these roots can lead to successful clonal reproduction upon contacting the soil. These strategies are evidently important in the persistence of ginkgo; in a survey of the "semiwild" stands remaining in Tianmushan, 40% of the specimens surveyed were multi-stemmed, and few saplings were present.
Sources: en.wikipedia.org
3-phosphoglycerate dehydrogenase deficiency 3-phosphoserine phosphatase deficiency Phosphoserine aminotransferase deficiency These enzyme defects lead to severe neurological symptoms such as congenital microcephaly and severe psychomotor retardation and in addition, in patients with 3-phosphoglycerate dehydrogenase deficiency to intractable seizures. These symptoms respond to a variable degree to treatment with L-serine, sometimes combined with glycine. Response to treatment is variable and the long-term and functional outcome is unknown. To provide a basis for improving the understanding of the epidemiology, genotype/phenotype correlation and outcome of these diseases their impact on the quality of life of patients, as well as for evaluating diagnostic and therapeutic strategies a patient registry was established by the noncommercial International Working Group on Neurotransmitter Related Disorders (iNTD). Besides disruption of serine biosynthesis, its transport may also become disrupted. One example is spastic tetraplegia, thin corpus callosum, and progressive microcephaly, a disease caused by mutations that affect the function of the neutral amino acid transporter A.
==== Creation of other synthetic psychedelics ==== The synthetic mescaline analogue 2,6-dibromomescaline was described by Arthur Heffter in 1901, although he is not known to have tested it and its psychedelic effects weren't reported until much later. The psychedelic effects of 3,4-methylenedioxyamphetamine (MDA), a synthetic analogue of mescaline that had been derived from amphetamine in 1910, were discovered by American chemist and pharmacologist Gordon Alles in 1930, but weren't subsequently published until 1959. 3,4,5-Trimethoxyamphetamine (TMA), another synthetic mescaline analogue, was first described in 1947 and its psychedelic effects were described in 1955. 2,4,5-Trimethoxyphenethylamine (2C-O), a synthetic positional isomer of mescaline, was synthesized and claimed to be psychedelic similarly to mescaline in 1931, but later trials found it to be inactive. Various synthetic tryptamine psychedelics, such as diethyltryptamine (DET), 4-PO-DET (CEY-19), and 4-HO-DET (CZ-74), were developed in the late 1950s. In addition, the synthetic α-alkyltryptamine analogues α-methyltryptamine (AMT; Indopan) and α-ethyltryptamine (AET; Monase), which are psychedelics and/or entactogens, were marketed and clinically used at non-hallucinogenic doses as antidepressants in the early 1960s, but were quickly withdrawn due to physical toxicity. Numerous synthetic psychedelic tryptamines were known by the mid-1970s. Alexander Shulgin, an American chemist working at Dow Chemical Company, tried mescaline by 1960.
177Lu is produced by bombarding the stable isotope 176Yb(which is found in monazite sand and the ores euxenite and xenotime) with neutrons. 176Yb turns into 177Yb which is unstable and has a half-life of 1.9 hours so it quickly decays into the medical isotope 177Lu. For mass production, it is better to produce 176Yb through fission reactors. This is the indirect production method and requires elaborate radiochemical separation, purification, and results in large amounts of radioactive waste. The direct method of producing 177Lu is by performing neutron irradiation on 176Lu to 177Lu. This is an inexpensive and effective method to produce Lu-177. In the United States, the main place that 177Lu is produced is the University of Missouri Research Reactor. Once produced, Lu-177 is stable for 72 hours if stored below room temperature. Freeze dried kits of Lutathera do show reduced effectiveness in radiation therapy but they maintain radiochemical purity. Lu-177 requires radiation shielding for handling. Lu-177 is stored and transported in a vial with lead/plexiglass shielding ready-to-use. Repeated production, timely delivery, and quick administration are important so that the therapy remains effective. Once transported to the hospital or cancer treatment / oncology center, the patient is prepped, all necessary tests are done, and the patient requires two separate IV sites for infusion. One site for radioactive Lu-177 infusion and one site for amino acid infusion. Amino acid infusion is needed to reduce radiation toxicity to the organs - specifically the kidneys.
The company began expanding outside of Texas in 2018 with the opening of a location off Interstate 10 in Baldwin County, Alabama, and has since opened stores in Georgia, Florida, Kentucky, South Carolina, Tennessee, Colorado, Missouri, Mississippi, Ohio, Virginia, and Arizona, with new locations planned for North Carolina, Louisiana, Idaho, and Oklahoma. A location in St. Augustine, Florida opened on February 23, 2021, and a location in Daytona Beach, Florida opened on March 22, 2021. The first Buc-ee's in Arkansas opened on August 17, 2026, in Benton, Arkansas. At the store opening, Aplin stated that he was directing the company to focus expansion in "conservative, business-friendly states". The first Buc-ee's in Wisconsin is planned to open in Oak Creek, Wisconsin in early 2028.
==== UCH37 ==== UCH37 is a Ubiquitin C-terminal hydrolase that activated upon binding the 26S proteasome through the ubiquitin receptor Rpn13. UCH37 is activated upon binding the proteasome through the C-terminal DEUBAD (DUB adaptor) domain that binds Rpn2.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.